Non-alcoholic fatty liver disease (NAFLD) is a common and potentially serious condition, characterized by an accumulation of fat in the liver unrelated to alcohol consumption. It is emerging as a significant public health concern worldwide, owing to its high prevalence and potential to progress to severe liver disease.
NAFLD is closely associated with metabolic syndrome, a cluster of conditions including obesity, type 2 diabetes, hypertension, and dyslipidemia. Other risk factors include age, ethnicity, and certain genetic polymorphisms. Furthermore, lifestyle factors such as physical inactivity and unhealthy diet also contribute to the development of NAFLD.
NAFLD is often asymptomatic and may be incidentally diagnosed during routine health checks. Diagnostic tools include imaging techniques such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI), and liver biopsy, the gold standard for diagnosing NAFLD. Non-invasive tests, including blood biomarkers and transient elastography, are increasingly used for risk stratification and monitoring disease progression.
The mainstay of NAFLD management is lifestyle modification, including weight loss, dietary changes, and increased physical activity. Pharmacological interventions may be considered in patients with advanced disease or those who fail to respond to lifestyle interventions. Emerging therapies targeting various aspects of the disease pathogenesis are under investigation. Regular follow-up is crucial for monitoring disease progression and managing complications.
Understanding NAFLD, its risk factors, and management strategies is vital for healthcare professionals to effectively manage this growing health concern. Early identification, risk stratification, and intervention can prevent disease progression and reduce the burden of NAFLD. Ongoing research will likely provide new insights into the pathogenesis and treatment of this complex disease.
1.
For the treatment of vestibular schwannomas in neurofibromatosis type 2, stereotactic radiosurgery has been found to be effective.
2.
FDA Advisors Recommend Galleri Multicancer Blood Test
3.
Women who miss their first mammogram face higher risk of breast cancer death, study finds
4.
Thriving while surviving: Understanding the social needs of cancer survivors
5.
Can Accelerated Salvage RT Improve Prostate Cancer Control?
1.
Fatigue and Work Participation in Blood Disease: A Comprehensive Review
2.
First-Line Immuno-Hematology Examinations: Essential Diagnostic Tools for Patient Care
3.
The benefits and risks of taking fludrocortisone for adrenal insufficiency
4.
The Algorithmic Revolution: How AI is Reshaping Precision Oncology from Bench to Bedside
5.
Childhood Cancer Prevention Through Modifiable Exposure Reduction
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
3.
Understanding Common Causes of Abnormal Blood Counts
4.
Hematologic Fatigue and Work Function: Clinical Implications, Pathophysiology, and Management
5.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation